Neuronetics, Inc.

STIM

US64131A1051

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 04:00:00 2025-01-21 pm EST			5-day change	1st Jan Change
2.240 ^USD	-8.94%		+3.70%	+39.13%

Jan. 13	Neuronetics, Inc. Announces Unaudited Revenue Results for Fourth Quarter and Full Year 2024	CI
Jan. 13	Neuronetics, Inc. Provides Earnings Guidance for the Full Year 2025	CI

Earnings Flash (STIM) NEURONETICS Reports Q1 Revenue $17.4M

May 07, 2024 at 08:11 am EDT

This article is reserved for members

Already a member?

Not a member ?

Free registration

Latest news about Neuronetics, Inc.

Neuronetics, Inc. Announces Unaudited Revenue Results for Fourth Quarter and Full Year 2024	Jan. 13	CI
Neuronetics, Inc. Provides Earnings Guidance for the Full Year 2025	Jan. 13	CI
Neuronetics, Inc. completed the acquisition of Greenbrook TMS Inc. (OTCPK:GBNH.F) from Madryn Health Partners II (Cayman Feeder), LP, fund managed by Madryn Asset Management, LP, 1315 Capital II, L.P. fund managed by 1315 Capital, LLC, Greybrook Health Inc. and others for $0.58 million.	Dec. 08	CI
Neuronetics, Inc., Q3 2024 Earnings Call, Nov 12, 2024	Nov. 12
Earnings Flash (STIM) NEURONETICS Reports Q3 Revenue $18.5M	Nov. 12	MT
Neuronetics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	Nov. 12	CI
Neuronetics, Inc. Provides Standalone Earnings Guidance for the Fourth Quarter and Full Year 2024	Nov. 12	CI
Neuronetics, Greenbrook Receive Interim Order for Special Meeting of Shareholders for Greenbrook	24-10-04	MT
Neuronetics, Inc. Expands Health Policies Enhance Tms Therapy Access for Adolescents and Adults	24-09-19	CI
William Blair Downgrades Neuronetics to Market Perform From Outperform	24-08-13	MT
Neuronetics Shares Slump as Q2 Results Fall Below Estimates; Merger Announcement	24-08-12	MT
Neuronetics, Inc., Q2 2024 Earnings Call, Aug 12, 2024	24-08-12
Neuronetics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	24-08-12	CI
Earnings Flash (STIM) NEURONETICS Reports Q2 Revenue $16.5M, vs. Street Est of $18.7M	24-08-12	MT
Neuronetics, Inc. Provides Earnings Guidance for the Third Quarter and Full Year 2024	24-08-12	CI
Neuronetics, Inc. entered into a definitive arrangement agreement to acquire Greenbrook TMS Inc. (OTCPK:GBNH.F) from Madryn Health Partners II (Cayman Feeder), LP, fund managed by Madryn Asset Management, LP and others for $1 million.	24-08-11	CI
Neuronetics, Inc. Announces Aetna Policy Update Expands TMS Availability for Adolescents with Depression	24-07-22	CI
Humana Is First Commercial Payer to Address TMS Therapy Coverage for Adolescents	24-05-15	CI
William Blair Upgrades Neuronetics to Outperform From Market Perform	24-05-14	MT
Neuronetics, Inc., Q1 2024 Earnings Call, May 07, 2024	24-05-07
Earnings Flash (STIM) NEURONETICS Reports Q1 Revenue $17.4M	24-05-07	MT
Neuronetics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	24-05-07	CI
Neuronetics, Inc. Provides Earnings Guidance for the Second Quarter of Fiscal Year 2024	24-05-07	CI
Neuronetics, Inc. Announces the Publication of Significant Clinical Findings in Brain Stimulation: Basic, Translational, and Clinical Research in Neuromodulation	24-04-10	CI
Neuronetics, Inc. Announces John K. Bakewell, Joseph H. Capper and Dr. Wilfred E. Jaeger Not Stand for Reelection to the Board	24-03-28	CI

Neuronetics, Inc. is a commercial-stage medical technology company. The Company is focused on designing, developing and marketing products for patients who suffer from neurohealth disorders. Its commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation (TMS) to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The NeuroStar Advanced Therapy System is used to treat adult patients with major depressive disorder (MDD). The Company intends to continue to pursue development of its NeuroStar Advanced Therapy System for additional indications. The Company sells its NeuroStar Advanced Therapy System and recurring treatment sessions in the United States. Its primary focus is on selling to psychiatrists, with primary care physicians and pain management specialists.

Employees

201

Sector

Advanced Medical Equipment & Technology

Calendar

2025-03-10 - Q4 2024 Earnings Release (Projected)

More about the company